HUTCHMED (China) Ltd: Form 20-F for the period ended Dec 31, 2023
Filed with the SEC on Feb 28, 2024 and accepted by EDGAR at Feb 28, 2024, 06:40 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2023-01-01 to 2023-12-31 | $838.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 12 months2023-01-01 to 2023-12-31 | $302.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2023-01-01 to 2023-12-31 | $18.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2023-01-01 to 2023-12-31 | $759.0k | us-gaap:InterestExpense |
| Income tax | 12 months2023-01-01 to 2023-12-31 | $4.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-01-01 to 2023-12-31 | $100.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | $0.12 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | $0.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 869,196,348 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | $219.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | $32.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2023-01-01 to 2023-12-31 | $9.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-12-31 | $283.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $1.10bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $1.28bn | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $403.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $536.4m | us-gaap:Liabilities |
| Long-term debt | At period end2023-12-31 | $48.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-12-31 | $31.2m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2023-12-31 | $31.2m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2023-12-31 | $730.5m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2023-12-31 | 871,256,270 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001104659-24-028454. Last ingested by Listed: Oct 29, 2026, 06:09 ET. Listed shows no prices and gives no investment advice.